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I~  Introduction of chronic macrolide antibiotic therapy to a Cystic 
Fibrosis population 
R Branagan, S.H. Chotirmall, A.M. Lyons, T.B. Low, N.G. McElvaney. Department 
of Respiratory Medicine; Beaumont Hospital, Dublin, Ireland 
Introduction: Chronic infection and exacerbations with Pseudomonas aeruginosa 
are the primary cause of morbidity and mortality in CF patients. Macrolide 
antibiotics exhibit immunomodulatory and antimicrobial properties and are of 
enhanced benefit in CF patients. A subgroup (15) of our CF population were 
recently commenced on Azithromycin therapy. We looked at possible benefits in 
3 outcome measures in these patients ince commencing Azithromycin: change in 
FEV1, weight and number of exacerbations. 
Methods: We reviewed patient histories, looking at FEV1 and weight (kg) at 0, 
6, and 12 months. The number of exacerbations 6 months prior to commencing 
treatment, and in the 12 months following initiation of treatment were analysed. 
For the purpose of this study, an exacerbation was defined as requiring antibiotics 
for a new infection (PO/IV), and did not necessarily indicate need for hospital 
admission. 
Results: There was a reduction in mean exacerbation rate of 2.44 in the 6 months 
prior to starting therapy, to 1.889 (95% CI 0.772 3.006, p-value 0.0039) and 
0.667 (95% CI 0.193 1.526, p-value 0.0156) at 6 months and 12 months post- 
initiation of therapy respectively. Similarly, there was a weight increase 12 months 
following initiation of macrolide therapy with a mean increase of 8.9 kg (95% CI 
2.7 15.1, p-value 0.004). There was no difference in FEV1 at 0, 6 and 12 months 
with 5 patients experiencing a drop in FEV1. 
Conclusions: Azithromycin therapy was associated with an increase in weight and 
fewer exacerbations than prior to commencing treatment over a one year period. 
There was no increase in FEV1. Patients not demonstrating animprovement in lung 
function will nevertheless derive benefit from Azithromycin therapy because of the 
decreased incidence of acute pulmonary exacerbations. 
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1~ Clinical and immunmodulatory effects of once weekly 
azithromycin treatment in Cystic Fibrosis patients chronically 
infected with Pseudomonas aeruginosa 
G. Steinkamp 1 , S. Schmitt-Groh~ 2, G. D6ring 3, D. Worlitzsch 3, D. Staab 4, 
R. Schubert 5, S. Zielen 5. For the MUCOMAX Study Group. 1Klinische 
Forschung, Hannover; 2 University Children ~' Hospital, Bonn; 3Institute of Medical 
Microbiology and Hygiene, Tiibingen; 4 Children ~' Hospital of Charitd, Berlin; 
5 University Children ~' Hospital, Frankfi~rt, Germany 
Rationale: Former studies have reported improvement in lung function in cystic 
fibrosis (CF) patients, chronically infected with Pseudomonas eruginosa (PA) after 
long term treatment with azithromycin (AZM) three times weekly. Data on the 
effects of AZM on inflammatory markers are scarce. 
Aims: To evaluate the clinical and immunmodulatory effects of AZM treatment 
after cessation of a two-week course of anti-PA antibiotics. 
Methods: In a double blinded trial 38 patients received either placebo or AZM 
once weekly for 8 weeks (AZM dosage: 20 29kg: 500mg, 30 39kg: 750mg, 
40 49kg: 1000mg, ~>50kg: 1,250mg). Pulmonary function tests (FEV1, IVC, 
FVC, FEF25 75), the serum markers LPS-binding protein (LBP) and C-reactive 
protein (CRP) and PA alginate in sputum samples were evaluated before (PRE) and 
after (POST) eight weeks of treatment. 
Results: Data were available from 38 patients receiving AZM (21, 14 male/7 female, 
mean age: 23.7 years) or placebo (17, 7 male/10 female, mean age: 26.3 years). 
After treatment, LBR CRP and PA alginate were significantly increased in the 
placebo group, but not in the AZM treatment group: LBP (PRE/POST AZM 8.0/8.9; 
placebo 7.5/14.5gg/ml, p<0.0001), CRP (PRE/POST AZM 7.30/8.2; placebo 
6.2/27.8mg/ml, p<0.021) PA alginate (PRE/POST AZM 253.2/338.2; placebo 
361.1/714.4 gg/ml, p < 0.017). Lung function declined similarly in both groups. 
Conclusion: An eight week course of AZM leads to decreases of pro-inflammatory 
markers and PA alginate in CF patients relative to untreated CF patients. 
I •  Telithromycin inhibits the production of virulence factors 
and biofilm formation of P. aeruginosa without affecting its 
proliferation in vitro 
N. Hoffmann, H. Krogh Johansen, N. Hoiby. Department of Clinical Microbiology, 
RigshosTitalet, Copenhagen, Denmark 
P aeruginosa (PA) causes chronic lung infection in cystic fibrosis (CF) patients 
by establishing an alginate containing biofilm. The emergence of PA resistance to 
antibiotics highlights the need to design novel strategies to treat infections. Drugs 
that have the potential to disrupt biofilms and inhibit virulence factors crucial for 
pathogenesis and quorum sensing (QS) without affecting the growth could slow the 
development of resistance. 
The ketolide telithromycin (TEL) is a compound normally used against Gram- 
positive bacteria. In vitro inhibitory effect of TEL on the synthesis of alginate and 
the production of QS regulated virulence factors as pyocyanin, elastase and chitinase 
was investigated in a stable, CF mucoid PA isolate NH57388A. At concentration 
between 2 16 gg/ml, TEL suppressed exoproducts secretion and biofilm formation 
without affecting the growth of the bacteria. 
These results indicate that TEL works as an anti-pathogenic compound by attenu- 
ating the virulence of PA without affecting the growth and may have a promising 
effect in preventing PA biofilms in the lungs of CF patients. 
l • A n  audit of the clinical impact of oral azithromycin in children 
with chronic Pseudomonas airway infection 
A. Shenoy, K.G. Brownlee, S.R Conway, M. Denton. Regional Paediatric Cystic 
Fibrosis' Unit, St..James' University Hospital, Leeds', UK 
Aim: A number of studies have shown a beneficial effect of azithromycin (AZM) 
in patients with chronic Pseudomonas aeruginosa (PA) airway infection. We 
performed a retrospective audit to compare clinical outcomes before and after 
starting AZM in a Paediatric population. 
Method: From January 2000 all children categorized as having chronic or inter- 
mittent airway infection with PA, using the Leeds criteria, were commenced on 
oral AZM. A review of the unit database identified 33 patients (3 to 15 years) who 
had received treatment for at least 12 months. Respiratory function tests, infection 
status, nutritional status, frequency of hospital admissions and treatment burden 
were compared 12 months before and 12 months after starting treatment. 
Results: Mean weight gain in the year after starting AZM was greater then in 
the year before (3.61 vs. 2.93 kg, p 0.73). Mean fall in FEV1 in the year prior 
to starting AZM was greater than in the year after starting treatment ( 5% vs. 
2.38%, p 0.42). There was a significant reduction in the number of courses of 
IV antibiotics (41 to 27) and episodes of hospital admission (25 to 15) in the year 
following the start of AZM (p 0.0113, 0.0255 respectively). Respiratory cultures 
were positive for methicillin resistant staphylococcus' aureus (MRSA) in 2 patients 
and AZM resistant staphylococcus aureus in 5 patients in the year after starting 
AZM. 
Conclusion: In this paediatric population with chronic or intermittent PA infection 
AZM taken three times a week resulted in a significant reduction in admission into 
hospital and courses of IV antibiotics. There was a small, but none significant, 
improvement in weight gain and reduction in decline of FEV1 after treatment. 
Careful monitoring is advised to detect he development of resistant SA. 
